379255-01-3

Basic information

• Product Name: 5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE
• Synonyms: 5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE
• CAS NO: 379255-01-3
• Molecular Formula: C₈H₈BrClO₃S
• Molecular Weight: 299.57
• Mol File: 379255-01-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Hygroscopic, Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly)
• CAS DataBase Reference: 5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE(379255-01-3)
• EPA Substance Registry System: 5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE(379255-01-3)

Safety Data

• Hazardous Substances Data: 379255-01-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE is used as a sulfonating agent for the synthesis of pharmaceutical compounds. Its ability to add a sulfonyl group to aromatic compounds makes it a key component in the development of various medications.
Used in Agrochemical Industry:
5-BROMO-2-ETHOXY-BENZENESULFONYL CHLORIDE is used as a reactive intermediate in the production of agrochemicals. Its role in adding sulfonyl groups to aromatic compounds contributes to the creation of effective agricultural chemicals for pest control and crop protection.

Upstream product

• 106-41-2 4-bromo-phenol 
• 588-96-5 4-bromoethoxybenzene 

Downstream Products

• 1260081-84-2 ethyl 4-(5-bromo-2-ethoxyphenylslulfonamido) benzoate 

Relevant articles and documents

Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold

Abstract: The BRD4 protein is associated with various diseases, which has been an attractive target for the treatment of cancer and inflammation. This paper is a follow-up to our previous studies, in which we report the structure-based design, synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold. The SARs focused on exploration of the 2′ or 3′ position to afford novel inhibitors that may avoid potential metabolically unstable site. The most potent inhibitor 13f exhibited high binding affinity to BRD4(1) with a ΔTm value of 7.8 °C as evaluated in thermal shift assay (TSA). The potent activity was also demonstrated by a peptide competition assay with an IC50 value of 0.21?μM. The docking studies revealed the binding mode of the compounds with the active site of BRD4(1). In addition, in silico predictions indicated that these compounds possessed good drug-likeness and pharmacokinetic profile. Graphic abstract: This paper is a follow-up to our previous studies, in which we report the structure-based design,synthesis, and evaluation of a new class of small-molecule BRD4 bromodomain inhibitors bearing a benzo[d]isoxazolscaffold.[Figure not available: see fulltext.].

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.